NCT01970475View on ClinicalTrials.gov

Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

526

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Arthritis, Rheumatoid
Interventions
BIOLOGICAL

ABP 501

Solution for subcutaneous injection in pre-filled syringe

BIOLOGICAL

Adalimumab

Solution for subcutaneous injection in pre-filled syringe

Trial Locations (11)

30328

Research Site, Sandy Springs

33458

Research Site, Jupiter

44130

Research Site, Middleburg Heights

45525

Research Site, Hattingen

48910

Research Site, Lansing

92395

Research Site, Victorville

R3A 1M3

Research Site, Winnipeg

S75 2EP

Research Site, Barnsley

NE29 8NH

Research Site, North Shields

IP4 5PD

Research Site, Suffolk

CF14 4XN

Research Site, Cardiff

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01970475 - Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter